Article Text
Therapeutics/Prevention
Randomised controlled trial
Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants
Statistics from Altmetric.com
Footnotes
Contributors KMD and KS contributed equally to writing and revising this manuscript.
Competing interests KMD serves as site primary investigator for multicenter trials sponsored by Sanofi, GSK, Grifols, Merck, Astra Zeneca and Regeneron and as primary investigator for investigator initiated trial funded by Merck. KMD is involved in advising activities for Eli Lilly and consulting activities for GSK. KS serves as site primary investigator for multicenter trials sponsored by Eli Lilly.
Provenance and peer review Commissioned; internally peer reviewed.